Ribonucleotide reductase inhibitors are a family of anti-cancer drugs that interfere with the growth of tumor cells by blocking the formation of deoxyribonucleotides (building blocks of DNA).
Examples include:
- motexafin gadolinium.[1]
- hydroxyurea[2]
- fludarabine, cladribine, gemcitabine, tezacitabine, and triapine[3]
- gallium maltolate, gallium nitrate[4]
See also
References
- ^ Zahedi Avval F, Berndt C, Pramanik A, Holmgren A (January 2009). "Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd)". Biochem. Biophys. Res. Commun.. doi:. PMID 19121624. http://linkinghub.elsevier.com/retrieve/pii/S0006-291X(08)02551-5.
- ^ Mayhew CN, Phillips JD, Cibull ML, Elford HL, Gallicchio VS (September 2002). "Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea". Antivir. Chem. Chemother. 13 (5): 305–14. PMID 12630679.
- ^ Tsimberidou AM, Alvarado Y, Giles FJ (August 2002). "Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies". Expert Rev Anticancer Ther 2 (4): 437–48. doi:. PMID 12647987. http://www.future-drugs.com/doi/abs/10.1586/14737140.2.4.437?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov.
- ^ Bernstein LR (1998). "Mechanisms of therapeutic activity for gallium". Pharmacol. Rev. 50: 665–682. http://pharmrev.aspetjournals.org/cgi/reprint/50/4/665.pdf.
External links
- Ribonucleotide reductase inhibitor entry in the public domain NCI Dictionary of Cancer Terms
This article includes text from the U.S. National Cancer Institute's public domain Dictionary of Cancer Terms
 |
This oncology article is a stub. You can help Wikipedia by expanding it. |
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
